Some one seems to have sold off big time?
Definitely especially with the amount of sellers today one trade over a million. And a few 500000 share sell offs. WHY?
*I now have 800000 shares. Jack
Mornington no worries, theres no need for people to disrespect offers. I aways read your input and find it useful and constructive. I 1st brought MXC last March at 3.9p on a recommendation from ii.
Unfortunately this share has nosed dived, not what I wanted. I know have 800k shares, now averaging 1.56. I top as and when looking to hold a million. This company will have its day I truely believe that.
Philmccrotch don't be disrespectful to mornington.
I read his post.
Good news after good news after good news, yet the SP still goes down.
Held this share since last March and over a year on a continuous drop in despite positive RNS?
It won't happen here because this is MXC kaka
Mrindia I understand your frustrations especially when you have as many shares as you claim. Why even think of selling out when you brake even.
You have been invested in HEMO now for a while.
Good news will come when its ready. Forget about twitter sit back and relax. No good moaning about the daily sp.
Look what happened to SAR recently
Totally agree Ad this gswitch has been a LSE member for a day and 8 post. Nothing but a nasty troll.
pb_logo_reversed-1
Hi R
Cannabinoids: The Investment Case.
Date: Wednesday 27 April 2022
Time: 18:00-19:00
Scientific research suggests that cannabinoids have significant potential as active skincare ingredients given their anti-inflammatory and antioxidant properties. This presents an exciting commercial opportunity given that the market for anti-aging products is projected to reach US$47.8 billion by 2027.
Join us for an introduction to Cellular Goods, a company that is driving innovation in this exciting new market through the combination of science and wellness with the launch of a new series of products using lab made cannabinoids.
Anna Chokina, CEO of Cellular Goods, and Alexia Blake, Head of Research & Product Development, will outline the benefits of non-psychoactive cannabinoids, describe the developing commercial opportunity and the strategy that is underpinning product launches.
Nick Osborne, Head of Content at PrimaryBid, will introduce the session before handing over to our guests. Finally, a Q&A session will give you the opportunity to connect directly to the executive team.